Overall, these data are consistent with an underlying mechanism whereby CFTR-induced decline in ARSB can contribute to malignancies associated with defective CFTR, and suggest that treatment with rhARSB may be beneficial in CF-associated malignancies. The gene discussed is CFTR; the disease is cystic fibrosis.